Management of hyperprolactinemia in patients receiving antipsychotics

CNS Spectrums

Volumn 9, Issue 8 SUPPL. 7, 2004, Pages 28-32

  Miller, Karen K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GESTAGEN; NEUROLEPTIC AGENT; PROLACTIN; TESTOSTERONE;

AMENORRHEA; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG INDICATION; ESTROGEN THERAPY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; MENTAL DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK FACTOR; SYMPTOM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 4444350507     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900002340     Document Type: Conference Paper

References (9)

1. Kleinberg DL, Davis JM, De Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61.
2. Kearns AE, Golf DC, Hayden DL, et al. Risperidone-associated hyperprolactinemia. Endocr Pract. 2000;6:425-429.
3. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57-61.
4. Klibanski A, Biller BM, Rosenthal DI, et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab. 1988;67(1):124-130.
5. Becker D, Liver O, Mester R, et al. Risperidone, butnotolanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003;64(7):761-766.
6. Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002;59(12):1147-1154.
7. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91:629-634.
8. Cohen LG, Biederman J, et al. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001;11(4):435-440.
9. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65(2):187-190.